Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer.

Hillerdal V, Essand M.

BioDrugs. 2015 Apr 10. [Epub ahead of print]

PMID:
25859858
2.

Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration.

Ramachandran M, Jin C, Yu D, Eriksson F, Essand M.

J Immunol. 2014 Sep 1;193(5):2287-96. doi: 10.4049/jimmunol.1400339. Epub 2014 Jul 21.

PMID:
25049358
3.

Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland NJ, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):7-15. doi: 10.1089/humc.2013.181.

PMID:
24649837
4.

A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.

Liljenfeldt L, Yu D, Chen L, Essand M, Mangsbo SM.

J Immunother. 2014 Apr;37(3):155-62. doi: 10.1097/CJI.0000000000000028.

PMID:
24598450
5.

Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.

Schenk E, Essand M, Kraaij R, Adamson R, Maitland N, Bangma CH.

Hum Gene Ther Clin Dev. 2014 Feb 18. [Epub ahead of print]

PMID:
24548052
6.

Immunological shielding by induced recruitment of regulatory T-lymphocytes delays rejection of islets transplanted in muscle.

Vågesjö E, Christoffersson G, Waldén TB, Carlsson PO, Essand M, Korsgren O, Phillipson M.

Cell Transplant. 2015;24(2):263-76. doi: 10.3727/096368914X678535. Epub 2014 Jan 29.

PMID:
24480306
7.

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.

Hillerdal V, Ramachandran M, Leja J, Essand M.

BMC Cancer. 2014 Jan 18;14:30. doi: 10.1186/1471-2407-14-30.

8.

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Jin C, Yu D, Čančer M, Nilsson B, Leja J, Essand M.

Hum Gene Ther. 2013 Aug;24(8):766-75. doi: 10.1089/hum.2012.132.

9.

An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.

Ramachandran M, Yu D, Wanders A, Essand M, Eriksson F.

Mol Ther. 2013 Nov;21(11):2008-18. doi: 10.1038/mt.2013.153. Epub 2013 Jul 2.

10.

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A.

Cancer Gene Ther. 2013 Jul;20(7):386-93. doi: 10.1038/cgt.2013.35. Epub 2013 Jun 21. Erratum in: Cancer Gene Ther. 2013 Dec;20(12):702. Karlsson, S C H [corrected to Karlsson, H];Loskog, S I A [corrected to Loskog, A].

PMID:
23788110
11.

Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.

Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O, Le Blanc K, Uhrbom L, Forsberg-Nilsson K, Westermark B, Adamson R, Maitland N, Fan X, Essand M.

PLoS One. 2013;8(1):e54952. doi: 10.1371/journal.pone.0054952. Epub 2013 Jan 25.

12.

Genetically engineered T cells for the treatment of cancer.

Essand M, Loskog AS.

J Intern Med. 2013 Feb;273(2):166-81. doi: 10.1111/joim.12020. Review.

13.

Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.

Muthana M, Rodrigues S, Chen YY, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F, Lewis CE.

Cancer Res. 2013 Jan 15;73(2):490-5. doi: 10.1158/0008-5472.CAN-12-3056. Epub 2012 Nov 20.

14.

T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells.

Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15877-81. Epub 2012 Sep 10.

15.

CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.

Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS.

J Neuroinflammation. 2012 May 30;9:112. doi: 10.1186/1742-2094-9-112.

16.

Islet engraftment and revascularization in clinical and experimental transplantation.

Molnár C, Essand M, Wennberg L, Berne C, Larsson E, Tufveson G, Korsgren O.

Cell Transplant. 2013;22(2):243-51. doi: 10.3727/096368912X640637. Epub 2012 May 8.

PMID:
22584061
17.

Virotherapy of neuroendocrine tumors.

Essand M.

Neuroendocrinology. 2013;97(1):26-34. doi: 10.1159/000336084. Epub 2012 Feb 29. Review.

PMID:
22378183
18.

Age-related somatic structural changes in the nuclear genome of human blood cells.

Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, Lyle R, Essand M, Eriksson F, Assimes TL, Iribarren C, Strachan E, O'Hanlon TP, Rider LG, Miller FW, Giedraitis V, Lannfelt L, Ingelsson M, Piotrowski A, Pedersen NL, Absher D, Dumanski JP.

Am J Hum Genet. 2012 Feb 10;90(2):217-28. doi: 10.1016/j.ajhg.2011.12.009. Epub 2012 Feb 2.

19.

Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M.

J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.

20.

In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.

Adamson RE, Frazier AA, Evans H, Chambers KF, Schenk E, Essand M, Birnie R, Mitry RR, Dhawan A, Maitland NJ.

Hum Gene Ther. 2012 Feb;23(2):218-30. doi: 10.1089/hum.2011.021. Epub 2011 Sep 9.

PMID:
21823897
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk